Two billionaires that are villains of the left and right take the spotlight in a key Wisconsin race
Columbine victim's death from health problems related to 1999 school shooting ruled a homicide
US wine shops and importers say Trump's threatened 200% tariff on European wines would kill demand
Miami Beach mayor wants to end lease of independent theater that screened Palestine documentary
Haiti gangs set fire to building once home to nation's oldest radio station
UAE to push for easier access to US chip technology, Blooomberg News reports
USPS signs agreement with Elon Musk's DOGE team for assistance
Jordan Spieth shows there's rarely a dull moment with his game at The Players
Kering appoints Demna as Gucci's artistic director
By Foo Yun Chee
BRUSSELS (Reuters) - U.S. pharmaceutical company Pfizer gained unconditional EU antitrust approval on Thursday for its proposed $43 billion acquisition of cancer drug maker Seagen.
Pfizer announced the deal in March, its largest purchase in a string of recent acquisitions thanks to a once-in-a-lifetime cash windfall from its COVID-19 vaccine and treatment.
The European Commission said the deal would not significantly reduce competition in the 27-country European Union nor would it have a negative impact on prices.
"The proposed merger would not raise competition concerns," the EU antitrust watchdog said in a statement.
Washington-based Seagen is a pioneer of antibody-drug conjugates, which work like "guided missiles" designed to destroy cancer while sparing healthy cells.
(Reporting by Foo Yun Chee)
